Paul McKenzie has become COO of CSL Behring, having left Biogen as it struggles following the failure of its late-stage Alzheimer’s candidate.

With increasing numbers of novel biopharma platforms vying for a voice and money, it's more difficult for investors to assign them proper values.

AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.

Ionis has a long-standing reputation for being science driven, but in its 30-year history the company had never told its own story—until now.

Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.

Gilead's Truvada for PrEP is only getting to about 10% of people who could benefit, according to testimony Thursday.

The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.

EMS Pharma, whose sister company Novamed bought Takeda’s Multilab last year, is reportedly the front-runner in the bidding process.